With the rapidly growing problems related to multi-resistant bacteria, and the constant risk of pandemics caused by new variations of viruses, this area is a major global challenge. Concurrently, new pharmaceuticals are being developed, many of which require new and advanced routes towards achieving their effect. Irrespective of the type of disease, the drug delivery principle is often inspired by how bacteria and viruses infect cells, but with the aim of making ill cells healthy.
As a university of technology, Chalmers provides technologies that can help to improve diagnosis of infections and many other diseases, and we work with analytical and imaging instrumentation for analysis of nanoparticles designed for drug delivery. One example of how we tackle these types of societal challenges on a broad front is illustrated by our work on developing molecular tools to identify and treat resistant bacterial infections, at the same time that our researchers are also studying the design of hospital environments to limit the spread of bacteria between patients and from patients to staff. A collaboration with the same breadth is also taking place in virus diagnostics, improved vaccination strategies and new drug delivery methods, which also involves cooperation with regional and national actors in industry.
One of the key tasks of this profile area in the Area of Advance is to serve as a natural point of contact between researchers at Chalmers and the University of Gothenburg, Sahlgrenska Academy and clinics at Sahlgrenska University Hospital – in close cooperation with existing actors such as the Center for Antibiotic Resistance Research (CARe) and AstraZeneca.